Aerovate Therapeutics, Inc.

AVTE · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$25,175-$67,785-$2,518-$5,430
Dep. & Amort.-$179$226-$221$8
Deferred Tax$0$0$0$0
Stock-Based Comp.$4,295$5,133$1,185$1,243
Change in WC$0$0$0-$6,104
Other Non-Cash-$1,065$25,891-$827-$764
Operating Cash Flow-$22,124-$36,535-$2,381-$11,047
Investing Activities
PP&E Inv.-$57-$136$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$148,592$0$0$0
Inv. Sales/Matur.$0-$12,850$12,850$13,129
Other Inv. Act.-$59$0$0$0
Investing Cash Flow-$148,708-$12,986$12,850$13,129
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$307
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$190,608$0$247
Financing Cash Flow$0$190,608$0$554
Forex Effect-$4$0$0$0
Net Chg. in Cash-$170,836$176,722$10,469$2,636
Supplemental Information
Beg. Cash$220,942$44,220$33,751$31,115
End Cash$50,106$220,942$44,220$33,751
Free Cash Flow-$22,181-$36,671-$2,381-$11,047
Aerovate Therapeutics, Inc. (AVTE) Financial Statements & Key Stats | AlphaPilot